Company Filing History:
Years Active: 2013-2015
Title: Innovations of Inventor Xin Tong
Introduction
Xin Tong is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 3 patents to his name, his work focuses on innovative solutions for cancer treatment.
Latest Patents
One of his latest patents is titled "Fully humanized anti-HER2 antibody, preparation method and use thereof." This invention provides a fully human anti-HER2 monoclonal antibody, characterized by specific amino acid sequences for both the heavy and light chain variable regions. The patent also discloses the nucleotide sequence encoding the antibody, along with the expression vector and host cell that comprise this sequence. The antibody is intended for use in manufacturing medicaments for tumor treatment.
Another significant patent is "Fully human monoclonal antibody to VEGF, preparation method and use thereof." This invention presents a fully human anti-VEGF monoclonal antibody, developed using antibody phage display technology. This antibody exhibits higher affinity and a stronger capacity for inhibiting tumor cell proliferation compared to the humanized antibody bevacizumab. It is designed for use in preparing anti-tumor medicines.
Career Highlights
Xin Tong is currently employed at Shanghai Biomabs Pharmaceuticals Co., Ltd. His work at this company has been instrumental in advancing therapeutic options for cancer patients. His innovative approaches and research have positioned him as a key figure in the biotechnology sector.
Collaborations
Xin collaborates with notable colleagues, including Chuan Li and Ying Kan. Their combined expertise contributes to the success of their projects and the development of groundbreaking therapies.
Conclusion
In summary, Xin Tong is a distinguished inventor whose work in monoclonal antibodies has the potential to transform cancer treatment. His patents reflect a commitment to innovation and improving patient outcomes.